ArticleFrontiers in immunology2025
Geniposidic acid inhibits OVA-induced asthma by suppressing allergic airway inflammation and regulating gut microbiota.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unveiling the pharmacological landscape of geniposidic acid: mechanisms of action, therapeutic benefits, and scientific challenges.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- GPX4 alleviates airway inflammation by suppressing 5-LO expression and regulating ferroptosis.Respiratory research · 2026Article
- Synergistic interactions of melatonin and glucocorticoids in alleviating allergic airway inflammation.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a serious chronic inflammatory disease of the respiratory system. In this study, we aimed to explore the role of geniposidic acid (GPA) in ovalbumin (OVA)-induced asthma in mice and to clarify its underlying mechanism. The mice were divided into control group, OVA group, OVA+GPA (12.5, 25, 50 mg/kg) groups. Inflammatory mediators were measured by ELISA. Gut microbiota was detected by 16S RNA sequencing. The results demonstrated that GPA attenuated OVA-induced lung injury, inflammatory cell infiltration, and mucus hypersecretion. OVA-induced IL-4, IL-5, IL-13, and IgE production was also inhibited by GPA. IFN-γ production was increased by GPA. Furthermore, GPA inhibited OVA-induced NF-κB activation and increased Nrf2 expression. In addition, GPA alleviated the dysbiosis of gut microbiota induced by OVA. After GPA treatment, the diversity and abundance of intestinal microbiota in asthma mice increased. At the phylum level, GPA significantly reduced the relative abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.